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INTRODUCTION
Almost 30 years ago, Pizzo et al. [1] published their landmark
study which prospectively evaluated 1,001 pediatric and young
adult cancer patients presenting with fever. Bacterial and fungal
organisms accounted for over 96% of microbiologically docu-
mented infection during febrile neutropenia. Since then, research
efforts have largely focused on strategies to reduce or prevent the
morbidity and mortality related to infections caused by bacterial
and fungal pathogens. However, the advent and clinical availabil-
ity of an array of sensitive and specific diagnostic tools have
afforded clinicians and researchers the opportunity to identify
previously undetected viral pathogens. More recent literature
has linked as many as 34% of fever and neutropenia episodes
to a viral pathogen [2]. Significant morbidity and mortality has
been attributed to viruses that cause a variety of presentations
either as primary or reactivation infections.
For the majority of clinically important viral pathogens in
oncology patients, treatment of active infection is limited by a
lack of effective antiviral therapies and the host’s compromised
immune system. Therefore, preventative and suppressive thera-
peutic measures are of paramount importance. The epidemiology
and relevance of some of the more common viral pathogens in
children with malignancy and those undergoing hematopoietic
cell transplant (HCT) are reviewed below. Some of the commonly
employed preventative and suppressive measures to combat these
viral pathogens are discussed and necessary areas for future
development in viral prevention are highlighted.
EPIDEMIOLOGY OF VIRAL INFECTIONS
The list of viral pathogens that have led to significant infec-
tions in pediatric patients with malignancy or those undergoing
HCT is lengthy [3]. The growth of this list is multi-factorial
including improved diagnostic modalities to identify previously
existing but unrecognized viral pathogens (e.g., human metapneu-
movirus (HMPV)) as well as previously identified viruses that
were thought to be inconsequential but are now considered as
important contributors to poor outcomes (e.g., human herpes virus
(HHV-6). The epidemiology of common respiratory, herpes, and
gastrointestinal viruses are briefly discussed below.
RESPIRATORY VIRUSES
Three relatively large prospective observational studies
performed comprehensive respiratory viral testing on children
presenting with malignancy and fever [4–6]. The incidence of
identified respiratory viral pathogens per febrile episode ranged
from 7% to 59%. The variation in frequency of identified patho-
gens is related to variation in the diagnostic tests utilized,
the specimen type collected, and the implications for testing
(screening vs. symptom guided testing). Across the three studies,
the more commonly identified viral organisms included rhinovi-
rus, respiratory syncytial virus (RSV), parainfluenza, influenza,
and adenovirus. Less frequently HMPV, human bocavirus, and
coronavirus were also identified. Although less data exist in
HCT recipients, one recent prospective study showed that with
surveillance PCR testing, 50% of patients receiving an allogeneic
HCT have a positive test for a primary respiratory pathogen [7].
The distribution of viral isolates was similar to that of children
with malignancy. Among the respiratory pathogens, RSV is of
particular concern for resultant mortality in high-risk patients. In
immunocompetent patients, RSV is often a self-limiting upper
respiratory infection. However, in patients with AML and HCT
recipients RSV can progress to a lower respiratory tract process.
In this setting RSV is associated with a 14% case fatality rate in
patients with AML and a 50% case fatality rate in pediatric
recipients of HCT [8,9].
In pediatric patients with malignancy and those receiving
hematopoietic stem cell transplants, bacterial and fungal infections
have been the focus of fever and neutropenia episodes for decades.
However, improved diagnostic capabilities have revealed viral
pathogens as a significant cause of morbidity and mortality. Because
of limited effective antiviral therapies, prevention of viral infections
is paramount. Pre-exposure and post-exposure prophylaxis and
antiviral suppressive therapeutic approaches are reviewed. Addi-
tionally, infection control practices specific to this patient popula-
tion are discussed. A comprehensive approach utilizing each of
these can be effective at reducing the negative impact of viral
infections. Pediatr Blood Cancer 2012;59:11–15.
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ADENOVIRUS
As noted above adenovirus is a commonly identified respira-
tory pathogen. However, adenovirus can also reactivate from
latent status and cause significant morbidity and mortality in
pediatric HCT recipients [10]. Adenovirus infection rates have
ranged from 4.9% to 41% with invasive disease rates ranging
from 1% to 17%. A number of these studies suggest that the rates
of adenovirus infection in pediatric HCT recipients are higher
than those in the adult population [11–16]. Case fatality rates of
adenovirus infection in which the death was directly attributable
to adenovirus range from 8% to 17% [11,13,14,17].
HERPES VIRUSES
Although primary herpes virus infections are possible, it is
their ability to reactivate from latency that results in the majority
of the herpes virus morbidity and mortality in children with
malignancy or those receiving HCT. Prospective surveillance test-
ing has detected CMV reactivation in 12.9–29% of pediatric
allogeneic HCT recipients [16,18,19]. Despite pre-emptive thera-
py as many as one-third of patients with CMV reactivation go on
to have CMV disease and between 33% and 75% of these patients
succumb to their CMV disease [18,19]. Without acyclovir sup-
pressive therapy, HSV reactivation is frequent in HSV seroposi-
tive adult HCT recipients (70–80%) and in adult leukemia patients
(50–60%) [20–23]. HSV reactivation seems to be less frequent in
children but can complicate episodes of fever and neutropenia and
prolong mucositis [24]. Similarly, herpes zoster reactivation is
common in pediatric HCT recipients (30–33% with 11% of these
going on to dissemination) and in patients with acute lymphoblas-
tic leukemia (ALL) (9–28%) [25–28]. Prospective surveillance of
pediatric allogeneic HCT recipients suggest that greater than 60%
will have evidence of EBV reactivation [29]. Of those with reac-
tivation 1.0–2.8% will develop post-HCT-PTLD which is associ-
ated with a mortality rate greater than 80% [29,30].
HHV-6 has gained significant attention as a concerning reacti-
vation virus in HCT recipients. When prospectively monitored by
serial plasma PCR testing, up to 67% of pediatric allogeneic HCT
recipients will have evidence of HHV-6 viremia [31]. Although
the extent to which HHV-6 impacts the post-transplant period is
not clear, HHV-6 has been implicated in various clinical compli-
cations: neurocognitive decline, encephalitis, delay in engraft-
ment, and secondary graft failure [32–34]. Complicating the
interpretation of positive PCR testing for HHV-6 is the potential
for inherited HHV-6 secondary to chromosomal integration.
Inherited HHV-6 is estimated to exist in 1% of the world’s popu-
lation. When present, inherited HHV-6 can be misinterpreted as
actual HHV-6 reactivation resulting in unnecessary medical inter-
ventions [35].
GASTROINTESTINAL VIRUSES
Traditionally, testing for primary stool viral pathogens has
been limited to antigen tests for rotavirus, and enteric adenovirus
serotypes 40 and 41. Specific incidence data for each of these
viruses in children with malignancy or those receiving HCT are
not available in the medical literature. Nonetheless the impact of
such infections relative to dehydration, prolonged hospital stays,
and persistent symptoms with the need for parenteral nutrition
has been well documented [36]. PCR testing has now made
identification of other gastrointestinal pathogens such as human
caliciviruses (norovirus and sapovirus) and astrovirus possible. As
with other gastrointestinal pathogens, symptoms are often more
pronounced and viral shedding prolonged in patients receiving
chemotherapy or those undergoing an HCT [37,38].
PREVENTATIVE MEASURES
Infection Control Measures
Infection control measures serve as a cornerstone of infection
prevention. These efforts are particularly important with regards
to primary respiratory and gastrointestinal viruses as many of
these pathogens have been linked to a nosocomial outbreak in
an oncology or HCT ward [39–44]. Arguably the most important
infection control component is maintaining healthcare worker
(HCW) compliance with hand hygiene. The World Health
Organization has proposed recommendations for appropriate
hand hygiene technique [45]. Unfortunately, physicians working
on oncology and pediatric intensive care units have been found to
have less than 60% compliance with appropriate hand hygiene
practices [46].
Attempts should also be made to reduce the potential for
HCWs to carry viral pathogens into the hospital. HCW compli-
ance with yearly influenza vaccine has been very poor [47]. Al-
though heavily debated [48,49], mandatory influenza vaccination
for HCWs has been successfully enacted and reasonably well
received at a large children’s hospital [47]. It is also necessary
that medical institutions maintain policies that prevent HCWs
from coming to work when symptomatic from a communicable
disease. In one survey of HCWs, 86% of those reporting a recent
respiratory infection stated that they provided patient care after
their symptoms had started [50]. Guidelines on work restriction in
this setting have been published and should be enforced [51].
Finally, patient visitors, both children and adults, can serve as a
reservoir for viral transmission to hospitalized children. Although
literature documenting the effectiveness of such screening practi-
ces is limited, it is reasonable to employ a policy by which
visitors are screened for symptoms consistent with an infectious
process and if present, are restricted from visitation.
Combining each of these infection control practices can ulti-
mately result in the reduction of nosocomial viral infections.
Therefore, collaboration with an infection control team can prove
be invaluable. For example, a comprehensive infection control
initiative has proven to be successful in reducing nosocomial
RSV infection in an HCT unit [52].
Pre-Exposure Prophylaxis
Vaccination is the most effective approach for pre-exposure
prophylaxis. Although a number of vaccines are live virus vac-
cines and thus contraindicated in immunocompromised children,
it is still important to encourage families to maintain compliance
with vaccine recommendations in all close family contacts. This
practice is referred to as ‘‘cocooning’’ which can help to provide
protection around the more vulnerable immunocompromised
patient [53]. Oral poliovirus vaccine (no longer administered in
the US) is the only live virus vaccine with a definitive contraindi-
cation for administration to household contacts of immunocom-
promised patients. The Advisory Committee on Immunization
Practices offers the suggestion that close contacts of patients
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with ‘‘severely weakened immune systems being cared for in a
protective environment’’ should not receive the live attenuated
nasal spray influenza vaccine (LAIV) [54], however this sugges-
tion is not supported by published data or the biology of the
vaccine. In actuality the LAIV may be superior to the trivalent
inactivated vaccine in preventing the transmission of wild-type
influenza virus from close contacts to immunocompromised
patients. In LAIV recipients local production of mucosal IgA
antibodies neutralize wild type virus at its portal of entry thus
limiting the potential for shedding of wild type virus. Additional-
ly, LAIV provides some protection against circulating influenza
strains not included in the vaccine. Furthermore, fear of transmis-
sion and subsequent infection from the attenuated and cold-
adapted vaccine virus is unfounded, as the LAIV virus cannot
replicate at core body temperatures [55]. Given this, it is not at all
surprising that there have been no cases of documented infection
from the attenuated virus in close contacts of LAIV recipients.
Vaccines available against the aforementioned viral pathogens
include influenza, varicella, and rotavirus. Of these, only the
former is routinely recommended for children with malignancy
or those undergoing HCT. Clearly, the immune status of the
patient at the time of vaccination will have a significant impact
on that patient’s response to the influenza vaccine but seroconver-
sion in children receiving chemotherapy is possible [56,57].
Additionally, influenza vaccination of children that recently
completed chemotherapy has been shown to reduce in the rate
of respiratory tract infections, hospitalization, and antibiotics
[58,59]. Despite the universal recommendation for influenza vac-
cination, only two-thirds of pediatric oncologists recommend the
vaccine to their patients [60]. It is never unsafe to administer the
inactivated influenza vaccine and thus it should be administered to
all children prior to the start of the influenza season. Even in
children with previously noted egg allergy, influenza vaccination
can be safely performed [61].
Although the varicella vaccine is a live attenuated vaccine,
there are multiple publications documenting the safety and effec-
tiveness of the vaccine after administration to children in remis-
sion for ALL with or without suspension of maintenance
chemotherapy [62,63]. However, the recommendation to hold
chemotherapy around the time of vaccination and the report of
a fatal event in a child with ALL after varicella vaccination has
raised concern about administering the vaccine routinely to
patients with ALL [64]. As for HCT recipients, it is safe to
administer live attenuated varicella vaccination when various
parameters are met (off all immunosuppressive agents, docu-
mented response to inactive vaccines, and demonstration of an
adequate absolute lymphocyte count and lymphocyte function)
[65]. Two small clinical trials have evaluated the efficacy of
heat inactivated varicella vaccine in three or four dose schedules
during the peri-transplant period among adult autologous and
allogeneic HCT recipients [66,67]. In a meta-analysis of the
two studies, there was a trend toward reduced herpes zoster in-
fection [58,68]. Unfortunately, heat inactivated varicella vaccine
is not currently available.
Two rotavirus vaccines (live, oral human-bovine pentavalent
vaccine, and the oral live attenuated monovalent vaccine) are
currently licensed in the United States. To date no data on the
safety or efficacy of either vaccine exist in children with malig-
nancy or those receiving HCT [69]. Therefore, neither can be
recommended for this patient population.
Post-Exposure Prophylaxis
Post-exposure prophylaxis is primarily limited to influenza and
varicella exposures. The efficacy of influenza chemoprophylaxis
in healthy household contacts of index influenza cases has been
well established in randomized trials [70,71]. Although random-
ized trials specific to immunocompromised patients have not been
performed, CDC recommendations support post-exposure chemo-
prophylaxis after close (face-to-face) exposure in an unvaccinated
patient [72]. Various regimens have been suggested, but typically
such prophylaxis should begin within 48 h and be continued for
10 days. The choice of the antiviral agent used should be guided
by the current year’s influenza sensitivity profile as reported by
the CDC. Influenza vaccine should also be administered to the
exposed individual.
Recommendations for varicella post-exposure prophylaxis are
provided in the 2009 Redbook: Report of the Committee on
Infectious Diseases [73]. Patients without a history of varicella
or unknown or negative varicella serologies and receiving chemo-
therapy for malignancy or recipients of HCT are considered at risk
for varicella infection after a true exposure. The definition of
‘‘true’’ exposure can be challenging but close face-to-face contact
with someone who has chicken pox or intimate contact with
someone who has herpes zoster are often considered real expo-
sures. Passive immunoprophylaxis within 96 h should be estab-
lished by administering Varicella Zoster Immunoglobulin
(VariZIG). VariZIG is available for routine use in Canada but in
the United States it must be administered via an investigational
new drug protocol from FFF Enterprises (800-843-7477; www.
fffenterprises.com/Products/VariZIG.aspx). If VariZIG is not avail-
able conventional intravenous immunoglobulin can be substituted.
If 96 h from the time of exposure has elapsed then immunopro-
phylaxis will be less effective. In this setting chemoprophylaxis
with acyclovir started 7–10 days after the exposure and continued
for 7 days can be administered. Fisher et al. [74] recently
reviewed the available data for the effectiveness of both of these
post-exposure approaches in immunocompetent and immunocom-
promised children. There are reasonably strong data to support the
effectiveness of immunoglobulin in reducing the risk of severe
disease in immunocompromised children. The data for the effec-
tiveness of acyclovir chemoprophylaxis in immunocompromised
children are limited to case reports and small case series. Howev-
er, this approach has been effective in exposed immunocompetent
children and thus it is considered a reasonable secondary option in
immunocompromised hosts [74].
Passive immunoprophylaxis (both pre-exposure and post-
exposure) against RSV for immunocompromised patients with
the monoclonal antibody palivizumab (Synagis), has been ex-
plored but the data are limited. A study of rats immunosuppressed
with 3 weeks of cyclophosphamide and exposed to RSV sug-
gested that respiratory viral replication can be reduced when
palivizumab is administered on the day prior to RSV inoculation
[75]. More recently, a decision tree mathematical model utilizing
estimated rates of RSV exposures, hospitalizations, and deaths in
pediatric HCT recipients concluded that monthly palivizumab
administration to HCT recipients would result in a 10% decrease
in mortality [76]. Although these data are compelling, the number
of assumptions that were made to execute the decision tree anal-
ysis makes it difficult to recommend this intervention for all
pediatric patients undergoing an HCT. Clearly, additional research
Viral Infections in Pediatric Malignancies 13
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is necessary to better define the benefits of palivizumab for pas-
sive prophylaxis in HCT recipients.
Suppressive Therapy
Data from clinical trials have supported the efficacy of pro-
phylaxis with ganciclovir compared to placebo in CMV seroposi-
tive HCT recipients [77]. However, neutropenia was a noted risk
in those receiving ganciclovir. In comparing ganciclovir to a
pre-emptive therapeutic approach, there was no difference in the
rate of CMV disease or death [78]. Additionally, foscarnet has
also been suggested in the peri-transplant period for high-risk
patients due to a decreased incidence of bone marrow suppres-
sion. No clear consensus exists and published adult recommen-
dations have supported either the prophylactic or pre-emptive
approach in higher-risk HCT recipients (e.g., seropositive recipi-
ent or donor, T-cell depleted transplant, or mismatched donor)
[78–80]. Although CMV disease has been reported in children
receiving chemotherapy for various malignancies, CMV prophy-
laxis in this patient population is typically not recommended [81].
In controlled trials, acyclovir prophylaxis has proven effective
in various adult HCT and malignancy patient populations
[22,23,82]. Given the high rate of HSV reactivation without sup-
pressive therapy, most adult guidelines support the administration
of acyclovir prophylaxis to HSV seropositive allogeneic HCT
recipients until engraftment and resolution of mucositis
[80,83,84]. A similar approach is suggested for HSV seropositive
pediatric HCT recipients. It has also been deemed reasonable to
administer acyclovir prophylaxis to adult and pediatric patients
with leukemia and receiving chemotherapy [81,84]. However,
monitoring for and treating clinically apparent breakthrough
HSV infections seems more prudent in non-HCT pediatric
patients as the frequency of HSV reactivation is likely much
less in children. In patients with frequent HSV recurrences pro-
longed acyclovir prophylaxis should be discussed with the family.
Combined pediatric and adult trials have demonstrated the
benefit of acyclovir prophylaxis at reducing herpes zoster epi-
sodes in VZV seropositive HCT recipient [85,86]. Based on these
data, more recently published guidelines support the administra-
tion of acyclovir to VZV serology positive allogeneic HCT recip-
ients for up to 1 year [84]. Although herpes zoster infections are
common in children with ALL, currently there are no recommen-
dations for prophylaxis in these patients as the time at risk is quite
prolonged. Instead clinical monitoring and treatment of herpes
zoster episodes is suggested. Acyclovir prophylaxis in patients
with ALL with two or more herpes zoster episodes should be
considered at least for the duration of chemotherapy exposure.
Data on the prophylactic use of antivirals directed at suppress-
ing the reactivation of adenovirus are limited. In 2006, an abstract
presentation at the European Study Group for Blood and Bone
Marrow Transplantations suggested that ribavirin prophylaxis
may be beneficial at reducing adenovirus infection and mortality
in pediatric HCT recipients versus historical controls [87]. These
data have yet to be published and currently most experts support
using cidofovir in a pre-emptive therapeutic approach, especially
among high-risk HCT recipients [88].
FUTURE DIRECTIONS
We have entered an era where advanced and commonly avail-
able diagnostic modalities have made it possible to identify the
presence of many viral pathogens. This technology has helped to
establish the significant impact that viral infections are having on
the morbidity and mortality of children with malignancy and
those receiving HCT. Despite this knowledge, there continues to
be a paucity of effective interventions available to prevent or
suppress these infections. Research efforts should focus on
discovering novel therapies that are both effective at preventing
and treating infection and that also have an attractive safety
profile. However, even when effective antiviral agents or vaccines
are available there is often a lack of data and consensus for best
practice recommendations. Therefore, at this time, establishment
of rigorous and consistent guidelines for both infection control
measures and prophylactic therapies may be the most effective
way to reduce the impact of viral pathogens. Such guidelines
should be formally proposed, evaluated and appropriately adjust-
ed by committees composed of experts representing the disci-
plines of oncology, infectious diseases, and infection control
and prevention.
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